Clinical trials: SSTR-expressing Tumors
Neuroendrocrine Tumors, Meningioma
Dosimetry Guided PRRT With 90Y-DOTATOC
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03013387
- Testing
- 90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids
- Sponsor
- Sue O'Dorisio
Neuroendocrine Tumors
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs…
- Trial name
- NCT01237457
- Testing
- 177Lu-DOTATATE
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Ebrahim S Delpassand
Neuroblastoma
A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
This study is a multicenter, open label phase I dose escalation trial designed to define the Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE in children with refractory or recurrent neuroblastoma.
- Trial name
- NEUROBLU 02 (NCT03966651)
- Testing
- PRRT with 177Lu-DOTATATE
- Where
- 14 sites in France
- Volunteers
- 1 people
- Sponsor
- Institut Claudius Regaud